5results about How to "Increase activity level" patented technology

The invention relates to the technical field of psychiatric pharmacology, discloses application of helicid in antidepressant drugs, and aims to solve the problems of large side effect, unstable curative effect, drug resistance and the like of existing antidepressant drugs. According to the medicine, through multiple mechanisms of activating a cAMP / PKA / CREB signal channel, promoting neuroplasticity, inhibiting neuronal apoptosis, relieving neuroinflammation and the like, the depressive symptom is remarkably improved. The preparation method comprises the steps of extraction and purification of helicid and preparation of the medicinal preparation. Animal experiments verify that the hilicidum-based antidepressant drug can effectively improve behavioral indexes of depression model rats, has low side effects, and does not have the problem of drug resistance. Compared with the traditional medicine, the medicine provided by the invention has the advantages that the treatment effect is improved, the adverse reaction is reduced, the application prospect is better, and a new medicine choice with a multi-target action mechanism is provided for the treatment of depression.

The invention provides a novel nano antibody-based recombinant long-acting human growth hormone fusion protein, nucleic acid, a pharmaceutical composition, application and the like. Existing long-acting means of PEGylation, Fc fusion and the like often cause reduction of activity, the human growth hormone is innovatively fused with an anti-albumin nano antibody with a specific sequence, and protein with larger molecules is formed through combination of the nano antibody and albumin antigen, so that the half-life period of the human growth hormone is prolonged, the activity of the human growth hormone is prolonged, and the human growth hormone can be used for preparing the anti-albumin nano antibody. In addition, the activity of the fusion protein provided by the invention is higher than that of a human growth hormone standard substance. The fusion protein and the like have wide industrial application prospects in the field of biological medicines.

The invention belongs to the field of photocatalytic materials, and particularly discloses a CdS-ZnSe heterojunction photocatalytic material with a {002} active crystal face high exposure ratio as well as a preparation method and application of the CdS-ZnSe heterojunction photocatalytic material. The CdS-ZnSe heterojunction is synthesized through a step-by-step reaction strategy. The method comprises the following steps: firstly, synthesizing a CdS nanosheet seed crystal with a hexagonal crystal phase through a cation exchange method, and then controllably preparing the CdS-ZnSe heterojunction with oriented growth in combination with a seed crystal growth method. The rate of the prepared CdS-ZnSe heterojunction for preparing H2 through photocatalytic decomposition of water under the condition of no metal promoter reaches 17.1 mmol.g <-1 >. H <-1 >, and compared with single-component CdS nanosheet seed crystal and ZnSe nanoparticles, the hydrogen production rate of CdS-ZnSe is greatly improved.

The invention discloses a method for increasing the content of gamma-aminobutyric acid in traditional Chinese medicine through fermentation. The method comprises the following steps: S1, superfine grinding of raw materials; s2, performing enzymolysis treatment; s3, fermentation treatment; lactobacillus plantarum and lactobacillus reuteri are selected to be matched for fermentation. A compound enzyme system (cellulase, pectinase and hemicellulase) is added, and the enzyme addition amount is 600 U / g-1400 U / g; the content of GABA in a bacterium synergistic fermentation system is obviously higher than that of a single bacterium fermentation system. Experimental data show that the GABA content can reach 131.5 + / -0.7 [mu] mol / g under the synergistic fermentation condition for 48 h, the GABA content under the lactobacillus plantarum single bacterium fermentation condition and the GABA content under the lactobacillus reuteri single bacterium fermentation condition are 45.5 + / -1.1 [mu] mol / g and 29.9 + / -2.1 [mu] mol / g respectively, the GABA yield is increased by about 2.9-4.4 times through synergistic fermentation, and it is proved that the method can effectively promote efficient conversion and accumulation of glutamic acid into GABA.

A method of compiling a treatment reference table that indicates the responsiveness of one or more specific mutations of α-Gal A to a specific pharmacological chaperone, the method comprising: analysing in vitro the response to the specific pharmacological chaperone in a host cell that has been transformed with a nucleic acid vector that encodes a first mutant α-Gal A and compiling a table listing responsive and non-responsive mutant forms of α-Gal A. The specific pharmacological chaperone is 1-deoxygalactonojirimycin or a pharmaceutically salt or ester and the first cell is HEK-293 MSR cell.